Animal Health & Veterinary Laboratories Agency, Weybridge, TB Research Group, New Haw, Addlestone, Surrey KT15 3NB, UK.
Expert Rev Vaccines. 2011 Jul;10(7):1083-91. doi: 10.1586/erv.11.22.
Significant progress has been made in the development of specific antigens that allow the differentiation of BCG-vaccinated and Mycobacterium bovis-infected cattle (the differential diagnosis of infected from vaccinated individuals test). This has been greatly facilitated by the completion of the genome sequences of Mycobacterium tuberculosis, M. bovis and BCG Pasteur and the application of comparative genome and transcriptome analysis to define differentiating infected from vaccinated animals (DIVA) antigens that complement the prototype DIVA antigens ESAT-6 and CFP-10. In this article we present an update of our current approaches including the search for stage-specific antigens, the identification of novel diagnostic biomarkers and the development of DIVA skin tests. We also discuss the possible cost-effective application of DIVA tests within the remits of a cattle BCG vaccine program.
在开发能够区分卡介苗接种牛和牛分枝杆菌感染牛的特定抗原方面取得了重大进展(感染与接种个体测试的差异诊断)。这得益于结核分枝杆菌、牛分枝杆菌和卡介苗 Pasteur 的基因组序列的完成,以及比较基因组和转录组分析的应用,以定义区分感染与接种动物(DIVA)的抗原,这些抗原补充了原型 DIVA 抗原 ESAT-6 和 CFP-10。在本文中,我们介绍了我们当前方法的更新,包括寻找阶段特异性抗原、鉴定新的诊断生物标志物和开发 DIVA 皮肤测试。我们还讨论了在牛卡介苗疫苗计划范围内,以具有成本效益的方式应用 DIVA 测试的可能性。